Clinical trial
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
NCT00125151 · Prothya Biosolutions, Industry · Completed
Key facts
| NCT number | NCT00125151 |
|---|---|
| Title | C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema |
| Official title | Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema |
| Lead sponsor | Prothya Biosolutions, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Angioedema |
| Intervention type | Drug |
| Interventions | C1 inhibitor concentrate (C1-esteraseremmer-N) |
| Enrollment | 15 |
| Start date | Feb 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Jul 29, 2005 |
| Last update posted | May 4, 2009 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: